文献速递青光眼眼底病与葡萄膜炎

噻吗洛尔对家族性青光眼患者诱导多能干细胞中OPTN聚集的影响

Effect of Timolol on Optineurin Aggregation in Transformed Induced Pluripotent Stem Cells Derived From Patient With Familial Glaucoma.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2018-01-01

本研究利用OPTNE50K突变正常眼压性青光眼患者来源的诱导多能干细胞分化的视网膜神经节细胞,发现噻吗洛尔可减少OPTNE50K聚集、增加ATH5阳性细胞、减少TUNEL阳性细胞、提高LC3B-II/LC3B-I比值并降低p62表达,提示其可能通过增强自噬流和神经保护作用成为OPTNE50K-NTG的潜在治疗药物。

要点

  • 噻吗洛尔减少OPTNE50K阳性面积及不溶性OPTNE50K,提示可减少OPTNE50K聚集。
  • 噻吗洛尔增加ATH5阳性细胞、减少TUNEL阳性细胞,提示神经保护作用。
  • 噻吗洛尔提高LC3B-II/LC3B-I比值并降低p62表达,提示可能增强自噬流。

核心结论

  • 作者认为噻吗洛尔应被视为OPTNE50K-NTG的潜在特异性治疗药物,因其可通过增强自噬流和神经保护作用减少E50K-iPSCs来源视网膜神经节细胞中的OPTNE50K聚集。

研究设计与样本

  • 研究为体外细胞实验,使用健康人来源诱导多能干细胞(WT-iPSCs)和OPTNE50K突变正常眼压性青光眼患者来源诱导多能干细胞(E50K-iPSCs)分化的视网膜神经节细胞。

主要发现

  • 体外OPTNE50K正常眼压性青光眼模型显示OPTNE50K聚集、星形胶质细胞活化、视网膜神经节细胞数量减少及凋亡性细胞死亡增强。
  • 噻吗洛尔减少OPTNE50K阳性面积并降低不溶性OPTNE50K,提示其具有减少OPTNE50K聚集的潜力。
  • 噻吗洛尔增加ATH5阳性细胞、减少TUNEL阳性细胞、提高LC3B-II/LC3B-I比值并降低p62表达。
  • 上述结果提示噻吗洛尔可能通过增强自噬流减少OPTNE50K聚集。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine a chemical agent that can reduce the aggregation of optineurin (OPTN) in cells differentiated from induced pluripotent stem cells obtained from a patient with normal-tension glaucoma (NTG) caused by an E50K mutation in the OPTN gene (OPTNE50K-NTG). METHODS: Retinal ganglion cells (RGCs) were created from induced pluripotent stem cells derived from a healthy individual (wild-type [WT]-iPSCs) and from a patient with NTG due to OPTNE50K (E50K-iPSCs) mutation. The death of the induced RGCs was evaluated by counting the number of TUNEL- and ATH5-positive cells. Axonal growth was determined by measuring the axonal length of TUJ1-positive cells. OPTN aggregation was assessed by measuring the OPTN-positive area by immunofluorescence and by Western blotting. Autophagic flux assay was investigated by determining the light chain 3 (LC3)B-II/LC3B-I ratio and p62 expression by Western blotting. RESULTS: The results showed OPTNE50K aggregation, activation of astrocytes, reduction in the number of RGCs, and enhancement of apoptotic cell death in the in vitro OPTNE50K model of NTG. Timolol was found to reduce the OPTNE50K-positive area and decreased the insoluble OPTNE50K, suggesting that it has the potential of reducing the OPTNE50K aggregation. Timolol also increased the ATH5-positive cells, decreased TUNEL-positive cells, increased the LC3B-II/LC3B-I ratio, and decreased the expression of p62. These findings suggest that timolol might enhance autophagic flux, leading to reduced OPTNE50K aggregation. CONCLUSIONS: Timolol should be considered a potential therapeutic agent specific to OPTNE50K-NTG because it can reduce the OPTNE50K aggregation in E50K-iPSCs-RGCs by enhancing autophagic flux and neuroprotective effects.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Inagaki S, Kawase K, Funato M, et al. Effect of Timolol on Optineurin Aggregation in Transformed Induced Pluripotent Stem Cells Derived From Patient With Familial Glaucoma. Invest Ophthalmol Vis Sci. 2018. PMID: 29847634. doi:10.1167/iovs.17-22975

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。